Why is NIOX Group (LSE:NIOX), an AIM-quoted medical device company, talking about returning excess Capital to shareholders when its first-half Revenue slipped? The answer comes from its 28 July 2026 trading update, which paired a modest revenue decline with a net cash position that the company regards as more than it currently needs.

A Focused Respiratory Diagnostics Business

NIOX Group describes itself as a medical device company specialising in point-of-care FeNO testing, used in the diagnosis and management of asthma and COPD. FeNO, or fractional exhaled nitric oxide, is measured from a patient's breath, and the group's NIOX devices are designed for use in clinics rather than central laboratories. Revenue is split between clinical sales, which include devices and consumable tests used by healthcare providers, and research sales to pharmaceutical and academic customers running clinical trials.

The group's stated 2026 priorities, set out in its AGM statement on 21 May 2026, are to deepen FeNO testing penetration in the United States, roll out its new NIOX PRO® device as regulatory approvals arrive, and advance NIOX MyNO, a device intended for home use. In the same statement, the company said it had secured a ten-year exclusive Supply agreement with its FeNO sensor supplier to support Investment in Manufacturing capacity.

The July Trading Update

On 28 July 2026, NIOX reported unaudited revenue of £24.0 million for the six months ended 30 June 2026, compared with £25.2 million a year earlier. Clinical revenue rose to £20.6 million from £20.0 million, while research revenue fell to £3.4 million from £5.2 million. The company said gross Margin was approximately 71% and adjusted EBITDA was £8.3 million, against £9.2 million in the first half of 2025.

Net cash stood at £16.8 million after paying a final Dividend of £6.5 million during the half. That compares with £22.3 million of cash at 30 April 2026 and £19.9 million at 31 December 2025, according to the AGM statement. The trading update said the company intends to return excess capital during the second half of 2026, with the mechanism to be detailed at its interim results, expected towards the end of September.

Guidance and Sector Conditions

NIOX said trading was in line with consensus expectations, which it put at revenue of £50.5 million and adjusted EBITDA of £17.5 million for 2026. It expects the second half to be stronger than the first, supported by the commercial rollout of NIOX PRO® and price increases in Japan, and it anticipates US and Japanese regulatory approvals during the second half. Chief executive commentary in the update stated: "Customer feedback following the launch of NIOX PRO® has been extremely encouraging, reinforcing our confidence in the opportunity ahead."

The split between the two revenue streams suggests clinical Demand held up while research revenue, which depends on the timing of pharmaceutical trials, proved more volatile.

Risks and What to Watch

The second-half outlook relies partly on regulatory approvals that had not been confirmed at the time of the update, and any delay could affect the NIOX PRO® rollout. Research revenue may remain uneven, and the group depends on a single sensor supplier, despite a long-term exclusive agreement. The size and form of any capital return had not been specified, so the interim results are the next key disclosure, alongside progress on US adoption and the MyNO home device.

Conclusion

NIOX is planning to return excess capital because, on its own figures, it remained cash generative and held £16.8 million of net cash at the end of June 2026 even after paying a £6.5 million dividend. Its revenue dipped because research sales fell, while clinical sales grew. Whether the second half delivers the improvement the company expects will depend largely on NIOX PRO® approvals and adoption.